



BioLineRx Ltd. Hosts Investor Breakfast Meeting in NY

December 5, 2017

TEL AVIV, Israel, Dec. 5, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE:BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today hosts its investor breakfast meeting at the Convene Conference Center near Grand Central in New York, NY.

Philip Serlin, Chief Executive Officer of BioLineRx, stated, "This annual event gives us the opportunity to directly meet with our investors for updates on our progress: steady advancements on our multiple clinical programs in stem cell mobilization, combination immunotherapies and acute myeloid leukemia (AML), as well as our new and novel immuno-oncology therapy. And we are pleased to feature a presentation by Dr. John DiPersio, Chief, Division of Oncology at Washington University School of Medicine, an internationally-renowned hematologist and expert on the role of CXCR4 in stem-cell mobilization and hematological malignancies. There remains a large, unmet need for cancer therapies and we remain focused on advancing programs that improve upon current treatments and the standard of care."

In addition to the keynote presentation by Dr. DiPersio on bone marrow transplantation and the role of CXCR4 in cancer, additional topics for discussion at the ongoing BioLineRx investor breakfast meeting include: (i) presentation on BL-8040 clinical development plans in immuno-oncology combinations and AML, as well as on the upcoming GENESIS Phase 3 study in stem cell mobilization for autologous bone-marrow transplantation in multiple myeloma patients; (ii) presentation of AGI-134, the Company's novel immuno-oncology project; and (iii) an overview of the Company's plans and expected milestones for 2018.

BioLineRx is hosting a live webcast of the investor breakfast today between 9:00-10:30 am ET. To access the webcast, please go to the [breakfast event page](#) on BioLineRx's website. An audio replay of the meeting will also be available for approximately three months following the meeting on the [breakfast event page](#).

About BioLineRx

BioLineRx is a clinical-stage biopharmaceutical company focused on oncology and immunology. The Company in-licenses novel compounds, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.

BioLineRx's leading therapeutic candidates are: BL-8040, a cancer therapy platform, which has successfully completed a Phase 2a study for relapsed/refractory AML, is in the midst of a Phase 2b study as an AML consolidation treatment and is expected to initiate a Phase 3 study in stem cell mobilization for autologous transplantation; and AGI-134, an immunotherapy treatment in development for multiple solid tumors, which is expected to initiate a first-in-man study in the first half of 2018. In addition, BioLineRx has a strategic collaboration with Novartis for the co-development of selected Israeli-sourced novel drug candidates; a collaboration agreement with MSD (tradename of Merck & Co., Inc.), on the basis of which the Company has initiated a Phase 2a study in pancreatic cancer using the combination of BL-8040 and MSD's KEYTRUDA; and a collaboration agreement with Genentech, a member of the Roche Group, to investigate the combination of BL-8040 and Genentech's atezolizumab in several Phase 1b/2 studies for multiple solid tumor indications and AML.

For additional information on BioLineRx, please visit the Company's website at www.bioprx.com, where you can review the Company's SEC filings, press releases, announcements and events. BioLineRx industry updates are also regularly updated on [Facebook](#), [Twitter](#), and [LinkedIn](#).

Various statements in this release concerning BioLineRx's future expectations constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "may," "expects," "anticipates," "believes," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; and the ability to implement technological improvements. These and other factors are more fully discussed in the "Risk Factors" section of BioLineRx's most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 23, 2017. In addition, any forward-looking statements represent BioLineRx's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.

Contact:

PCG Advisory
Vivian Cervantes
Investor Relations
+1-646-863-6274
vivian@pcgadvisory.com

or

Tsipi Haitovsky
Public Relations
+972-52-598-9892
tsipihai5@gmail.com

View original content: <http://www.prnewswire.com/news-releases/biolinerx-ltd-hosts-investor-breakfast-meeting-in-ny-300566737.html>

SOURCE BioLineRx Ltd